What is considered a high cut-off filter in dialysis, and is the F180 (Fresenius 180) filter considered high cut-off?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

High Cut-Off Dialysis Filters: Definition and F180 Classification

High cut-off (HCO) dialyzers are defined as membranes with pore sizes up to 50 kDa (compared to 5 kDa in standard dialyzers), and the F180 (Fresenius Theralite™) is indeed considered a high cut-off filter with a molecular weight cut-off of approximately 45-60 kDa. 1, 2, 3

Technical Definition of High Cut-Off Filters

Standard vs. High Cut-Off Membranes:

  • High-flux dialyzers are defined by β2-microglobulin clearance of at least 20 mL/min and molecular weight cut-offs around 5 kDa 1
  • High cut-off dialyzers have molecular weight cut-offs up to 50 kDa, allowing removal of molecules significantly larger than conventional membranes 1, 4
  • The molecular weight retention onset (MWRO) provides a classification system that clearly differentiates low-flux, high-flux, protein-leaking, and high cut-off membrane families 5

The F180/Theralite™ as a High Cut-Off Filter

Specific Characteristics:

  • The Fresenius Theralite™ (F180) filter is specifically designed to remove plasma substances with molecular weights up to 45 kDa, including free light chains 2, 3
  • This filter can reduce serum free κ light chains by more than 75% over 6 weeks of treatment 2
  • During hemodialysis with the Theralite™, phenytoin clearance averaged 80.1 mL/min, demonstrating its enhanced removal capacity for larger molecules 3

Clinical Applications and Important Caveats

Primary Uses:

  • Myeloma cast nephropathy: HCO dialyzers can reduce serum free light chain levels by >70%, with two randomized trials (MYRE and EuLITE) showing mixed results on renal recovery 1
  • The MYRE trial demonstrated significantly higher renal recovery at 6 months (56.4% vs 35.4%, OR 2.37, p=0.04) and 12 months (60.9% vs 37.5%, OR 2.59, p=0.02) with HCO dialysis 1
  • Removal of proinflammatory cytokines in sepsis and larger middle molecules in end-stage renal disease 4

Critical Limitations:

  • Albumin loss is the major concern - HCO membranes are more permeable than the glomerular filtration barrier before blood exposure, though they become tighter after blood contact 5, 6
  • Albumin losses with HCO dialysis are prohibitive against long-term use in chronic hemodialysis patients 6
  • The EuLITE study showed inferior age-adjusted overall survival (HR 2.63, p=0.03) with HCO dialysis, possibly due to higher infectious complications (31% vs 9% pulmonary infections) 1

Practical Distinction from Standard High-Flux

Key Differences:

  • High-flux membranes (20 mL/min β2-microglobulin clearance) are recommended for reducing β2-amyloidosis and may reduce cardiac mortality in patients dialyzed >3.7 years 1
  • High cut-off filters go beyond high-flux capabilities, targeting molecules 10-fold larger (up to 50 kDa vs 5 kDa) 1, 4
  • HCO filters require supplementation with low-flux filters or careful monitoring to prevent excessive albumin loss 6

The F180/Theralite™ is definitively a high cut-off filter, not merely high-flux, based on its 45-60 kDa molecular weight cut-off and clinical applications targeting free light chains and larger molecules. 2, 3, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Phenytoin overdose treated with hemodialysis using a high cut-off dialyzer.

Hemodialysis international. International Symposium on Home Hemodialysis, 2017

Research

High cut-off dialysis membranes: current uses and future potential.

Advances in chronic kidney disease, 2011

Research

High cut-off dialysis in chronic haemodialysis patients.

European journal of clinical investigation, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.